Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii plus triple therapy in H. pylori-related peptic ulcer
ChiCTR2500111294Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Oct 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of saccharomyces boulardii in Peptic ulcer disease (PUD), gastric ulcer and Helicobacter pylori infection (2 arms), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: HP eradication rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
saccharomyces boulardii
03
Conditions
Peptic ulcer disease (PUD)gastric ulcerHelicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2500111294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111294.